Understanding mechanism of efficacy and resistance of CAR-T cell therapies in cancer
Felipe Prosper
Head of the Hematology and Cell Therapy Department, University of Navarra
Despite the success of CAR-T cells from the treatment of patients with hematological malignancies, over 40% of the patients are resistant to therapy or eventually relapse. Our lab is interested in overcoming some of the current limitations of CAR-T including decreasing the cost of production, understanding current mechanisms involved in efficacy and resistance in hematological malignancies and in solid tumors or the engineering of new CAR-Ts. To address this questions we have been working with non-viral systems of production of CAR-T cells, the use of multiomics technologies to understand mechanism of resistance, or the development of new CAR-T constructs based on SdAb from camelids. I will review some of our recent published studies as well as novel information